2-氨基-3-甲基吡嗪 | 19838-08-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氨基-3-甲基吡嗪
• 中文别名: 3-甲基-2-氨基吡嗪
• 英文名称: 3-methylpyrazin-2-amine
• 英文别名: 2-amino-3-methylpyrazine；3-Amino-2-methylpyrazin；2-Amino-3-methyl-pyrazin
• CAS: 19838-08-5
• 化学式: C₅H₇N₃
• 分子量: 109.131
• InChiKey: VQPHZDDLWFHRHR-UHFFFAOYSA-N

物化性质

• 熔点：
  165-167 °C
• 沸点：
  194.6°C (rough estimate)
• 密度：
  1.1118 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Amino-3-methylpyrazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-3-methylpyrazine
CAS number: 19838-08-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H7N3
Molecular weight: 109.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-3-甲基吡嗪 在 Selectfluor 、 lithium bromide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以80%的产率得到2-氨基-5-溴-3-甲基吡嗪
  参考文献：
  名称：

  使用LiCl / LiBr对2-氨基吡啶和2-氨基二嗪进行Selectfluor促进的区域选择性氯化/溴化。

  摘要：

  使用LiCl作为氯源，可以在温和条件下在Selectfluor和DMF存在下建立2-氨基吡啶或2-氨基二嗪的氯化反应。该方法以高至高收率和高区域选择性得到氯化吡啶或二嗪。而且，该方法扩展到通过使用LiBr来溴化2-氨基吡啶或2-氨基二嗪。氯化反应的区域选择性在很大程度上取决于2-氨基吡啶或2-氨基二嗪中的取代基模式。探索了由氯化吡啶合成布帕利西布的方法。对机理的研究表明，这种氯化反应是通过吡啶或二嗪自由基过程进行的。

  DOI：

  10.1039/c9ob00972h
• 作为产物：
  描述：

  2-azido-3-methylpyrazine 在 盐酸 、 tin(ll) chloride 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以40%的产率得到2-氨基-3-甲基吡嗪
  参考文献：
  名称：

  Studies on Pyrazines; Part 30:¹Synthesis of Aminopyrazines from Azidopyrazines

  摘要：

  叠氮吡嗪不能通过有效制备烷基或芳基胺的试剂进行还原，因为杂环叠氮化物以双环形式存在于四唑[1,5-a]吡嗪中。然而，通过在氨 hydroxide 和钯-炭存在下进行加氢裂解，或通过在醇溶盐酸中用氯化锡(II)还原，成功转化为氨基吡嗪，产率为34-87%。为了阐明反应的成功进展，通过1H NMR光谱在不同溶剂中检查了叠氮-四唑的平衡。

  DOI：

  10.1055/s-1994-25607

文献信息

• [EN] BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE URÉE, THIOURÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078408A1

  公开（公告）日：2014-05-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  式I化合物或其立体异构体、互变异构体或药学上可接受的盐、溶剂合物或前药，其中环A、环C和X如本文所定义，是TrkA激酶的抑制剂，并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：AVISTA PHARMA SOLUTIONS INC

  公开号：WO2020160075A1

  公开（公告）日：2020-08-06

  The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.

  本公开描述了新颖化合物或其药用盐、含有它们的药物组合物以及它们的医药用途。本公开的化合物具有前列腺素EP4受体拮抗剂的活性，并且在治疗或缓解疼痛和炎症以及其他与炎症相关的疾病，如关节炎，治疗或预防疼痛、炎症性疾病等疾病或医疗状况方面具有用处。本文还描述了通过给予本公开的化合物（即EP4受体拮抗剂）来治疗疼痛的方法。
• Biaryl Ether Urea Compounds
  申请人：FAY Lorraine Kathleen

  公开号：US20080261941A1

  公开（公告）日：2008-10-23

  The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.

  本发明涉及式(I)的化合物或其药用可接受的盐；制备该化合物的方法；制备该化合物所用的中间体；含有该化合物的组合物；以及利用该化合物治疗与脂肪酸酰胺水解酶(FAAH)活性相关的疾病或症状。
• [EN] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS<br/>[FR] COMPOSÉS INDOLIQUES UTILES EN TANT QUE MODULATEURS DU RÉCEPTEUR DES ANDROGÈNES
  申请人：NIDO BIOSCIENCES INC

  公开号：WO2022020342A1

  公开（公告）日：2022-01-27

  Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

  本文提供了一种公式（V）的化合物，它们与雄激素受体（AR）的BF3结合，可以调节AR以治疗肯尼迪病。
• [EN] 4- [HETEROCYCLYL-METHYL] -8-FLUORO-QUINOLIN-2-ONES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS<br/>[FR] 4-[HÉTÉROCYCLYLMÉTHYL]-8-FLUORO-QUINOLIN-2-ONES UTILES COMME INHIBITEURS DE L'OXYDE NITRIQUE SYNTHASE
  申请人：KALYPSYS INC

  公开号：WO2009029625A1

  公开（公告）日：2009-03-05

  Novel compounds of formulae (II, III) and pharmaceutical compositions have been found to inhibit inducible NOS synthase wherein: R4, R5, R6 and R7 are independently selected from the group consisting of hydrogen, lower alkyl, and halogen; and, R8 has the structure whrein X1, X2, X3, X4, X5, X6, R9, R13, R14 and n are as described herein.

  已发现具有式（II，III）的新化合物和药物组合物能够抑制可诱导型NOS合酶，其中：R4、R5、R6和R7分别选自氢、较低烷基和卤素组成的群；而R8具有结构，其中X1、X2、X3、X4、X5、X6、R9、R13、R14和n如本文所述。

表征谱图